GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT04680767

CompletedPhase 1Results posted

A Study of LY3502970 in Healthy Male Participants

Disposition of [¹⁴C]-LY3502970 Following Oral Administration in Healthy Male Participants

Lead sponsor

Eli Lilly and Company

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 18-32•Male•Healthy volunteers

Primary endpoints

•Feces Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage•Urinary Excretion of LY3502970 Radioactivity Over Time Expressed as•Fecal Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04680767

Org study ID17784

Secondary IDJ2A-MC-GZGFEli Lilly and Company

Timeline

Milestones

Study first posted2020-12-23actual

Study start2021-03-29actual

Primary completion2021-07-03actual

Study completion2021-07-03actual

Last update posted2026-05-26actual

Results first posted2026-05-26actual

Assets

Investigational agents

Orforglipron

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age35 Years

Maximum age55 Years

SexMale

Healthy volunteersAccepted

Inclusion criteria

•Are overtly healthy males

•Body weight within 50 and 100 kilograms (kg), inclusive, and body mass index within the range 18.0 and 32.0 kilograms per square meter (kg/m²) (inclusive)

Exclusion criteria

•Females

•Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product (IP); or of interfering with the interpretation of data

•Have a history of Gilbert's syndrome or have total bilirubin level (TBL) above upper limit of normal (ULN) at screening

•Have evidence of significant active neuropsychiatric disease, as determined by the investigator

•Have had any exposure to LY3502970 or any other glucagon-like peptide-1 (GLP-1) analogs, or other related compounds within the prior 3 months, or any history of allergies to these medications

•Are currently enrolled in a clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study

•Have participated, within the last 3 months, in a clinical study involving an IP. If the previous IP has a long half-life, 5 half-lives or 3 months (whichever is longer) should have passed, prior to check-in

•Have participated in any clinical trial involving a radiolabeled IP within 12 months prior to check-in

•Show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies

•Show evidence of hepatitis C and/or positive hepatitis C antibody

•Show evidence of hepatitis B and/or positive hepatitis B surface antigen

•Have had exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing (e.g., serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)

Endpoints (16)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

16 endpoints

Primary/registry result

Feces Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Time frame:0, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, and 384 hours (h) postdose

descriptive

Posted result

Group	Value (mean), percentage of the total radioactive dose	95% CI
3mg [¹⁴C]-LY3502970	86.75	—

Primary/registry result

Urinary Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Time frame:0, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, and 384 hours (h) postdose

descriptive

Posted result

Group	Value (mean), percentage of the total radioactive dose	95% CI
3mg [¹⁴C]-LY3502970	0.24	—

Primary/protocol endpoint

Fecal Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Time frame:Predose up to Day 17 after administration of study drug

percent change from baseline, descriptive

Primary/protocol endpoint

Urinary Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Time frame:Predose up to Day 17 after administration of study drug

descriptive

Secondary/registry result

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve t, Where t is the Last Time Point With a Measurable Concentration (AUC0- Tlast) of Plasma LY3502970

Time frame:Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogramhour per milliliter(ngh/mL)	95% CI
3mg [¹⁴C]-LY3502970	210	—

Secondary/registry result

PK: Area Under the Concentration Versus Time Curve t, Where t is the Last Time Point With a Measurable Concentration ((AUC0- Tlast) of Total Radioactivity in Plasma and Whole Blood

Time frame:Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogram equivalents*hour per milliliter	95% CI
3mg [¹⁴C]-LY3502970AUC0-tlast of Plasma Total Radioactivity	266	—
AUC0-tlast of Whole Blood Total Radioactivity	103	—

Secondary/registry result

PK: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC (0-∞)] of Plasma LY3502970

Time frame:Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogramhour per milliliter(ngh/mL)	95% CI
3mg [¹⁴C]-LY3502970	223	—

Secondary/registry result

PK: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC (0-∞)] of Total Radioactivity in Plasma and Whole Blood

Time frame:Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogram equivalents*hour per milliliter	95% CI
3mg [¹⁴C]-LY3502970AUC(0-∞) of Plasma Total Radioactivity	292	—
AUC(0-∞) of Whole Blood Total Radioactivity	135	—

Secondary/registry result

PK: Maximum Concentration (Cmax) of Plasma LY3502970

Time frame:Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogram per milliliter(ng/mL)	95% CI
3mg [¹⁴C]-LY3502970	10.4	—

Secondary/registry result

PK: Maximum Concentration (Cmax) of Total Radioactivity in Plasma and Whole Blood

Time frame:Predose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384 hours (h) postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogram equivalents per milliliter	95% CI
3mg [¹⁴C]-LY3502970Cmax of Plasma Total Radioactivity	10.7	—
Cmax of Whole Blood Total Radioactivity	5.92	—

Secondary/registry result

Total Number of Metabolites of LY3502970 in Plasma, Urine and Feces

Time frame:Plasma: 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 h postdose; Urine: -12 to 0, 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384h postdose

concentration, descriptive

Posted result

Group	Value (number), number of metabolites	95% CI
3mg [¹⁴C]-LY3502970Plasma	2	—
Urine	NA	—
Feces	12	—

Secondary/protocol endpoint

Plasma Pharmacokinetics (PK): Area under the Concentration-Time Curve (AUC) of LY3502970

Time frame:Predose up to Day 17 after administration of study drug

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Plasma PK: Maximum Concentration (Cmax) of LY3502970

Time frame:Predose up to Day 17 after administration of study drug

Cmax

concentration, descriptive

Secondary/protocol endpoint

Plasma and Whole Blood PK of Radioactivity: AUC

Time frame:Predose up to Day 17 after administration of study drug

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Plasma and Whole Blood PK of Radioactivity: Cmax

Time frame:Predose up to Day 17 after administration of study drug

Cmax

concentration, descriptive

Secondary/protocol endpoint

Relative Abundance of LY3502970 and it's Metabolites in Plasma, Feces, and Urine

Time frame:Predose up to Day 17 after administration of study drug

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.